For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab may delay clinical decline.

Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...

Researchers at Washington University in St. Louis are making potential findings in delaying the onset of Alzheimer’s symptoms ...

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

Alzheimer's disease is usually associated with old age. But around 5%-10% of all Alzheimer's cases occur in people under the age of 65. Early-onset ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

An experimental drug reduced the risk of developing symptoms of Alzheimer's disease by half in people with a rare genetic ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that could be effective at preventin ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...